Aprazer Healthcare Launched SUTEKAST

September 29, 2021
Posted by Aprazer

26 Feb

Launch Date: 26/02/21

Aprazer Healthcare Launched SUTEKAST (Sunitinib) which is a medication indicated for the treatment of rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. SUTEKAST is indicated for the treatment of advanced kidney cancer (advanced renal cell carcinoma or RCC). SUTEKAST is indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. SUTEKAST is indicated for the treatment of pancreatic neuroendocrine tumors (pNET) with progression & cannot be treated with surgery.

Newer Aprazer Healthcare to manufacture world class Oncology Drugs at state-of-the-art Manufacturing facility

Older Aprazer Healthcare Launched XGRAF

Disclaimer : This medical information is intended only for healthcare professionals in India. The products discussed herein may have different product labeling in other countries. The information within this site is intended to provide balanced, scientific, and evidence based answers to unsolicited medical questions. For full Prescribing Information including indications, contraindications, warnings, precautions, and adverse events, please submit a medical information request. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient. The website does not sell/ purchase any medicine.